Rabbit Recombinant Monoclonal TM41B antibody. Suitable for WB, IP and reacts with Human samples.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
WB | IP | IHC-P | Flow Cyt (Intra) | ICC/IF | |
---|---|---|---|---|---|
Human | Tested | Tested | Not recommended | Not recommended | Not recommended |
Mouse | Not recommended | Not recommended | Not recommended | Not recommended | Not recommended |
Rat | Not recommended | Not recommended | Not recommended | Not recommended | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/1000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/30 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Select an associated product type
Phospholipid scramblase involved in lipid homeostasis and membrane dynamics processes (PubMed:33850023, PubMed:33929485, PubMed:34015269). Has phospholipid scramblase activity toward cholesterol and phosphatidylserine, as well as phosphatidylethanolamine and phosphatidylcholine (PubMed:33850023, PubMed:33929485, PubMed:34015269). Required for autophagosome formation: participates in early stages of autophagosome biogenesis at the endoplasmic reticulum (ER) membrane by reequilibrating the leaflets of the ER as lipids are extracted by ATG2 (ATG2A or ATG2B) to mediate autophagosome assembly (PubMed:30093494, PubMed:30126924, PubMed:30933966, PubMed:33850023, PubMed:33929485, PubMed:34015269, PubMed:34043740). In addition to autophagy, involved in other processes in which phospholipid scramblase activity is required (PubMed:33850023). Required for normal motor neuron development (By similarity). (Microbial infection) Critical host factor required for infection by human coronaviruses SARS-CoV-2, HCoV-OC43, HCoV-NL63, and HCoV-229E, as well as all flaviviruses tested such as Zika virus and Yellow fever virus (PubMed:33338421, PubMed:33382968). Required post-entry of the virus to facilitate the ER membrane remodeling necessary to form replication organelles (PubMed:33382968).
KIAA0033, TMEM41B, Transmembrane protein 41B, Protein stasimon
Rabbit Recombinant Monoclonal TM41B antibody. Suitable for WB, IP and reacts with Human samples.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
TMEM41B also known as Transmembrane Protein 41B is part of the ER membrane protein complex that plays a fundamental role in various cellular processes. It is a 35 kDa protein located predominantly in the endoplasmic reticulum membrane. TMEM41B shows expression in many tissues including heart brain kidney and skeletal muscle suggesting its important role across different biological systems.
This protein functions in autophagy a process essential for cellular homeostasis and survival during stress conditions. TMEM41B associates with the ER-phagy complex where it is important for the regulation and expansion of autophagosomes. It works in coordination with proteins like VMP1 and ATG9A supporting the recruitment and stability of autophagosomal membranes which impacts the cell's ability to recycle and reuse cellular components.
TMEM41B has a significant involvement in the autophagy and lipid metabolism pathways. It interacts with other proteins such as VMP1 and ATG9A mediating the lipid mobilization necessary for efficient autophagosome formation. These interactions ensure that TMEM41B plays a role in the homeostatic regulation of lipids and proteins contributing to proper cellular function and response to metabolic demands.
TMEM41B associates with conditions like neurodegeneration and certain viral infections. Alterations or deficiencies in TMEM41B can impact its autophagic function potentially leading to neurodegenerative diseases where protein aggregates accumulate as seen in relation to ATG9A dysfunction. Additionally studies link TMEM41B to the flavivirus life cycle suggesting its necessity in viral replication processes. These connections highlight its potential as a therapeutic target in disease management.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Blocking and diluting buffer and concentration: 5% NFDM/TBST.
In Western blot, Anti-GAPDH antibody [EPR16891] - Loading Control (Anti-GAPDH antibody [EPR16891] - Loading Control ab181602) staining at 1/200000 dilution.
All lanes: Western blot - Anti-TMEM41B antibody [EPR28149-41] (ab314763) at 1/1000 dilution
Lane 1: 293T (human embryonic kidney epithelial cell) transfected with scrambled siRNA control whole cell lysate at 20 µg
Lane 2: 293T transfected with siRNAs specifically targeting TMEM41B whole cell lysate at 20 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution
Observed band size: 32 kDa
Exposure time: 180s
Blocking and diluting buffer and concentration: 5% NFDM/TBST.
Exposure time: Lane 1:180 seconds
Lane 2: 59 seconds
Lane 3: 26 seconds
All lanes: Western blot - Anti-TMEM41B antibody [EPR28149-41] (ab314763) at 1/1000 dilution
Lane 1: NCI-H1299 (human lu carcinoma epithelial cell) whole cell lysate at 20 µg
Lane 2: HCT-15 (human colorectal carcinoma epithelial cell) whole cell lysate at 20 µg
Lane 3: PC-3 (human prostate adenocarcinoma epithelial cell) whole cell lysate at 20 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution
Observed band size: 32 kDa
TMEM41B was immunoprecipitated from 0.35 mg 293T (human embryonic kidney epithelial cell) whole cell lysate with ab314763 at 1/30 dilution (2ug in 0.35mg lysates). Western blot was performed on the immunoprecipitate using ab314763 at 1/1000 dilution. VeriBlot for IP secondary antibody(HRP)(VeriBlot for IP Detection Reagent (HRP) ab131366) was used at 1/5000 dilution.
Lane 1: 293T (human embryonic kidney epithelial cell) whole cell lysate
Lane 2: ab314763 IP in 293T (human embryonic kidney epithelial cell) whole cell lysate
Lane 3: Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) instead of ab314763 in 293T whole cell lysate
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
All lanes: Immunoprecipitation - Anti-TMEM41B antibody [EPR28149-41] (ab314763) at 1/30 dilution
All lanes: 293T (human embryonic kidney epithelial cell) whole cell lysate
All lanes: Immunoprecipitation - VeriBlot for IP Detection Reagent (HRP) (VeriBlot for IP Detection Reagent (HRP) ab131366) at 1/5000 dilution
Exposure time: 3min
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com